Compare MOD & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOD | QGEN |
|---|---|---|
| Founded | 1916 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.2B |
| IPO Year | 1995 | 1998 |
| Metric | MOD | QGEN |
|---|---|---|
| Price | $236.96 | $41.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $223.71 | $50.26 |
| AVG Volume (30 Days) | 978.3K | ★ 1.4M |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.79% |
| EPS Growth | ★ 12.87 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $1,352,500,000.00 | N/A |
| Revenue This Year | $23.05 | $8.18 |
| Revenue Next Year | $21.83 | $5.71 |
| P/E Ratio | $263.92 | ★ $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $67.80 | $38.80 |
| 52 Week High | $260.01 | $57.82 |
| Indicator | MOD | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 47.29 |
| Support Level | $129.39 | $38.80 |
| Resistance Level | $238.19 | $48.60 |
| Average True Range (ATR) | 14.47 | 0.85 |
| MACD | 2.81 | 0.49 |
| Stochastic Oscillator | 64.20 | 76.80 |
Modine Manufacturing Co provides thermal management solutions to diversified markets and customers. The company provides engineered heat transfer systems and heat transfer components for use in on- and off-highway original equipment manufacturer (OEM) vehicular applications in the United States. It offers powertrain cooling products, such as engine cooling assemblies, radiators, condensers, and charge air coolers; auxiliary cooling products, including power steering and transmission oil coolers. Its operating segments include Climate Solutions and Performance Technologies.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).